当胆固醇与组胺相遇时，会产生树突状生成素A：一种肿瘤抑制代谢物。
When cholesterol meets histamine, it gives rise to dendrogenin A: a tumour suppressor metabolite.
作者信息
Poirot Marc, Silvente-Poirot Sandrine
机构信息
Sterol Metabolism and Therapeutic Innovations, Cancer Research Center of Toulouse, INSERM UMR 1037, University of Toulouse, F-31037 Toulouse, France Institut Claudius Regaud, Institut Universitaire du Cancer, F-31059 Toulouse, France
出版信息
Biochem Soc Trans. 2016 Apr 15;44(2):631-7. doi: 10.1042/BST20150232.
Dendrogenin A (DDA) is the first steroidal alkaloid (SA) to be identified in human tissues to date and arises from the stereoselective enzymatic conjugation of 5,6α-epoxycholesterol (5,6α-EC) with histamine (HA). DDA induces the re-differentiation of cancer cellsin vitroandin vivoand prevents breast cancer (BC) and melanoma development in mice, evidencing its protective role against oncogenesis. In addition, DDA production is lower in BCs compared with normal tissues, suggesting a deregulation of its biosynthesis during carcinogenesis. The discovery of DDA reveals the existence of a new metabolic pathway in mammals which lies at the crossroads of cholesterol and HA metabolism and which leads to the production of this metabolic tumour suppressor.
树突状细胞生成素A（DDA）是迄今为止在人体组织中发现的首个甾体生物碱（SA），它由5,6α-环氧胆固醇（5,6α-EC）与组胺（HA）通过立体选择性酶促共轭反应生成。DDA在体外和体内均可诱导癌细胞重新分化，并可预防小鼠乳腺癌（BC）和黑色素瘤的发生，证明其对肿瘤发生具有保护作用。此外，与正常组织相比，BC中DDA的生成量较低，这表明其生物合成在致癌过程中发生了失调。DDA的发现揭示了哺乳动物中一种新的代谢途径的存在，该途径处于胆固醇和HA代谢的交叉点，并导致这种代谢性肿瘤抑制因子的产生。
Zotero 插件